BioXcel Therapeutics Inc. published a document detailing results from a Phase 3 study evaluating BXCL501 (sublingual dexmedetomidine) for the treatment of agitation associated with bipolar disorder or schizophrenia in the home setting. The document reports on the safety and efficacy of BXCL501, noting that the treatment was safe and well tolerated over a 12-week period, with consistent reduction in agitation symptoms and no increase in adverse events with repeat dosing. The full document can be accessed through the link below.